A closer look at our newest research center at Yale University The American Parkinson Disease Association (APDA) is proud to support nine Centers for Advanced Research which, along with a variety of funded grants and fellowships, are the backbone of our research program. At these Centers, some of the most compelling PD research is underway – research […]
Dr. Gilbert chats with Dr. Okeanis Vaou about how climate may affect PD Living with Parkinson’s disease (PD) often means learning to adapt to changes in movement, thinking, and overall health. What many people don’t realize is that the environment, particularly temperature, humidity, and altitude—can also have a significant effect on symptoms. Recently, APDA’s Chief […]
What is Young Onset Parkinson’s Disease? When Parkinson’s disease (PD) is diagnosed between the ages of 21 and 50, it is called young onset, or early onset Parkinson’s disease (YOPD). Though symptoms overlap with typical PD, younger people face unique challenges, and even some surprising advantages, in managing the disease. Who Gets Young Onset […]
Tips for Traveling with Parkinson’s Disease People travel for many reasons – to see family, for business purposes, to explore new sites or just to relax and unwind. Traveling often brings unexpected challenges, especially for those with Parkinson’s disease (PD). However, with proper and proactive planning, there is no need to let PD hold you […]
Supporting Innovative Scientists and Breakthrough Discoveries The American Parkinson Disease Association (APDA) proudly announces $4.04 million in new funding for cutting-edge Parkinson’s disease (PD) research – representing a 55% increase in research funding from the previous year. These new awards support a remarkable group of scientists, each dedicated to advancing our understanding of PD and […]
Parkinson’s disease (PD) is typically diagnosed based on clinical exam, but there are imaging tests that are available to help in diagnosis. The most commonly known in the US is the Dopamine Transporter Scan (DaTscan), an imaging test in which a radioactive tracer, Ioflupane (123I) — which is also called DaTscan — is injected into the […]
Hospitalization can be stressful and challenging for anyone, but for people living with Parkinson’s disease (PD), a hospital stay can present unique risks. It is important for patients and their loved ones to be prepared for these situations in order to mitigate issues that may arise and have a chance at the best possible outcome. […]
How Adaptive DBS Aims to Offer More Personalized and Effective Therapy When the Food and Drug Administration (FDA) approved deep brain stimulation (DBS) for Parkinson’s disease (PD) in 2002, it revolutionized the PD treatment landscape. DBS has since become a very effective therapy for certain patients whose symptoms are no longer adequately controlled by medication […]
How Nanocarriers Overcome a Major Hurdle in Parkinson’s Treatment Delivering medications to the brain is one of the most significant challenges in modern medicine. The brain is protected by an incredibly selective shield known as the blood-brain barrier (BBB), a defense mechanism that keeps out toxins and harmful agents but also prevents many therapeutic drugs […]
What is neuromodulation and how can it be used to treat Parkinson’s disease? Medication remains the primary method of treating Parkinson’s disease (PD). However, neuromodulation, or therapies that involve the manipulation of brain circuitry, can also be very effective in controlling PD symptoms in particular clinical situations. Two current neuromodulatory techniques for PD are deep […]
Simple Email Signup v2 (Salsa replacement form)
